Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy.

[1]  B. Sjöquist,et al.  Ocular and systemic pharmacokinetics of latanoprost in humans. , 2002, Survey of ophthalmology.

[2]  H. Dua,et al.  Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension , 2001, The British journal of ophthalmology.

[3]  J. Rouland,et al.  Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. , 2001, Acta ophthalmologica Scandinavica.

[4]  L. Larsson.  The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. , 2001, Acta ophthalmologica Scandinavica.

[5]  German and Austrian ImipenemCilastatin Study Group,et al.  The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  J. Rouland,et al.  Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with β adrenergic antagonists , 2000 .

[7]  R. Weinreb,et al.  Glaucoma in the 21st century , 2000 .

[8]  K. Emmerich.  Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension — A 3-month randomised study , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  Bucci Mg,et al.  Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. , 1999, Journal of glaucoma.

[10]  M G Bucci,et al.  Intraocular Pressure-Lowering Effects of Latanoprost Monotherapy versus Latanoprost or Pilocarpine in Combination with Timolol , 1999 .

[11]  R. Schumer,et al.  Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. , 1998, American journal of ophthalmology.

[12]  R. P. Mills,et al.  Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. , 1998, American journal of ophthalmology.

[13]  P. Watson.  Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. , 1998, Ophthalmology.

[14]  A. Alm,et al.  The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. , 1997, Survey of ophthalmology.

[15]  R. P. Mills,et al.  Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. , 1997, Survey of ophthalmology.

[16]  R. Brubaker,et al.  Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. , 1997, Survey of ophthalmology.

[17]  A. Alm,et al.  Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. , 1997, Survey of ophthalmology.

[18]  R. Schumer,et al.  Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. , 1996, Ophthalmology.

[19]  M. Araie,et al.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. , 1996, Archives of ophthalmology.

[20]  L. Bito,et al.  Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. , 1996, Archives of ophthalmology.

[21]  C. Camras.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. , 1996, Ophthalmology.

[22]  J. Stjernschantz,et al.  A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. , 1996, Ophthalmology.

[23]  A. Alm,et al.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. , 1995, The British journal of ophthalmology.

[24]  A. Alm.  Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

[25]  P. Hoyng,et al.  Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. , 1994, The British journal of ophthalmology.

[26]  S. Hayreh,et al.  Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. , 1994, American journal of ophthalmology.

[27]  R. Brubaker,et al.  The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. , 1993, Archives of ophthalmology.

[28]  A. P. Moriarty,et al.  Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. , 1993, Archives of ophthalmology.

[29]  M. Yablonski,et al.  Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes , 1993 .

[30]  T. Puustjärvi,et al.  Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. A controlled multicenter study of 48 weeks. Scandinavian Timpilo Study Group. , 1992, Archives of ophthalmology.

[31]  B. Binkowitz,et al.  A Fixed Combination of Timolol and Pilocarpine: Double‐Masked Comparisons with Timolol and with Pilocarpine , 1992 .

[32]  P. Kaufman,et al.  Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey , 1989 .

[33]  S. Nilsson,et al.  Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. , 1989, Experimental eye research.

[34]  L. Bito,et al.  The ocular effects of prostaglandins and other eicosanoids. , 1989, Progress in clinical and biological research.

[35]  O. Hayaishi.  Advances in Prostaglandin, Thromboxane, and Leukotriene Research , 1985 .

[36]  R. Brubaker,et al.  Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. , 1985, Investigative ophthalmology & visual science.

[37]  R. Brubaker,et al.  Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma. , 1982, Ophthalmology.

[38]  R. Brubaker,et al.  The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. , 1982, American journal of ophthalmology.

[39]  M. Yablonski,et al.  Fluorophotometric study of epinephrine and timolol in human subjects. , 1981, Archives of ophthalmology.

[40]  R. Brubaker,et al.  The mechanism of timolol in lowering intraocular pressure. In the normal eye. , 1978, Archives of ophthalmology.

[41]  T. Zimmerman,et al.  A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. , 1978, Experimental eye research.

[42]  A. Bill,et al.  The Effects of Pilocarpine on the Dynamics of Aqueous Humor in a Primate (Macaca Irus) , 1966 .

[43]  B. Becker,et al.  Aqueous humor dynamics; theoretical considerations. , 1956, American journal of ophthalmology.